1-Durability of antibody responses 8.4 months after COVID-19 primary vaccination was significantly higher with Moderna mRNA-1273 than with Pfizer-BNT162b2. 4/
2-However, no difference was seen in vaccine effectiveness
3-Antibody responses and vaccine effectiveness were lower but not significantly different for JNJ-Ad26.COV2.S (statistical uncertainty in the small Ad26.COV2.S group). 5/
Viral dynamics & duration of PCR positivity of the #Omicron variant
In this study, longitudinal RT-qPCR tests collected between July 5th 2021 & January 10th 2022. This included 97 Omicron infections and 107 confirmed Delta infections 1/
Here are trajectories from individuals detected ≤1 day or ≥2 days since a previous negative or inconclusive test. 2/
Omicron infection duration was similar to Delta (both ~10 days), but Omicron infections had lower peak viral loads (higher peak Ct values). 3/
What happens if we allow #SARS2 to become endemic? What’s going to happen to us & what’s going to happen to the virus?
If we allow it to become endemic—and some would argue that it is already endemic—this does not mean that it is going to attenuate, not whatsoever. 1/
It is not true that more transmissible versions of #SARS2 will be more benign. What we are seeing is more aggressive, more transmissible versions which are creating more severe illness. And the virus is still adapting to our physiology. It’s doing it at a fantastic rate 2/
What we’re going to see is that it will continue to work against our immune systems, meaning become more immune evasive. It’s going to become more chronic as an infection. 3/
Booster effectiveness against breakthrough coronavirus infection is already waning.
The protection against infection among Pfizer booster recipients ages 60+ topped out by day 30 then fell steadily. 1/
By day 58, the #booster appeared to be providing around 40% of the maximum increased level of protection above the initial 2-dose series.
New data finds boosters are helping more than just 50+, but that the effects already appear to be decreasing. 2/
Bottom line: The case for boosters to prevent infection for all adults is now far stronger, if that is our goal. But how long that protection lasts remains unclear at best and boosters may turn out to lower the #Ro of #SARS2 only briefly. 3/